Tirzepatide vs semaglutide: real-world data

A multicentered real-world study published 30 June 2026 in Mayo Clinic Proceedings found that tirzepatide produced significantly greater weight loss than semaglutide at 12 months, with a better gastrointestinal tolerability profile. The study enrolled 511 adults with obesity across multiple US clinical sites, making it one of the larger head-to-head real-world comparisons of the two leading GLP-1 class drugs published to date^[1].

The numbers from the Mayo Clinic study

Over 12 months, tirzepatide-treated patients lost a mean of 16.6% of total body weight (standard deviation 8.6%), compared with 13.4% (SD 8.0%) for semaglutide-treated patients^[1]. The difference was statistically significant (P less than .01). The cohort was 74.8% female, 91.8% White, and had a mean BMI of 40.0 kg per square metre at baseline. Tirzepatide patients numbered 207; semaglutide patients 304.

The gap widened when researchers looked at higher response thresholds. Among tirzepatide recipients, 56.8% reached at least 15% total body weight loss, versus 40.7% on semaglutide (P equal to .03). For a 20% threshold, the figures were 39.0% versus 22.1%^[1]. In the sub-group without type 2 diabetes, tirzepatide produced 18.5% versus 14.2% mean weight loss (P less than .01).

On tolerability, gastrointestinal adverse events were reported by 28.5% of tirzepatide patients and 50.7% of semaglutide patients (P less than .01)^[1]. The lower GI burden with tirzepatide in a clinical setting is consistent with what has been reported in randomised trials, though direct dose-for-dose comparisons across studies are complicated by different titration schedules and baseline characteristics.

How this fits with other real-world evidence

The Mayo study is not the only real-world comparison published in 2026. A propensity-matched analysis in PNAS Nexus, published 16 June 2026 and covering 20,678 patients, found tirzepatide produced a mean 14.7% weight reduction versus 10.8% for semaglutide over one year (P less than .001), with high-response rates (at least 15% weight loss) nearly doubling^[2]. The PNAS study also reported lower gastrointestinal and systemic adverse-event prevalence with tirzepatide.

Both studies are observational, which means patient selection, prescriber preference, and unmeasured confounders can all shape the apparent treatment effect. Patients who received tirzepatide may have been different in ways the researchers could not fully account for, even after statistical adjustment. Real-world data complements randomised trial evidence by showing how drugs perform in everyday clinical practice, but it does not replace the causal inference that comes from randomised assignment.

What the Mayo study does not settle

Three limits are worth stating. First, this is a real-world cohort, not a randomised controlled trial. Randomised head-to-head evidence for weight loss specifically is available only from SURMOUNT-5, which compared the two drugs at their highest approved doses in adults with obesity or overweight without diabetes. SURMOUNT-5 enrolled a population that had already demonstrated tolerability on GLP-1 therapy, which may not represent all patients starting treatment for the first time.

Second, the Mayo cohort is predominantly White and predominantly female. The PNAS Nexus propensity-matched study found meaningful demographic variation in treatment response, with Black and Hispanic patients over-represented in the minimal-weight-loss category for both drugs. Whether the advantage seen for tirzepatide in the Mayo study holds equally across more diverse populations is a question these data cannot answer.

Third, neither study resolves the long-term question. At 12 months, both drugs are typically still in or near their maximum-effect window. The durability of the tirzepatide advantage beyond year one, and the weight-regain trajectory if treatment is discontinued, are separate questions. The SURMOUNT-4 discontinuation trial showed substantial weight regain when participants switched to placebo at week 36, but that evidence applies to a clinical-trial population and a shorter observation window.

What clinicians and patients should take from this

The Mayo Clinic Proceedings study adds real-world texture to the incretin head-to-head picture. Across both randomised and observational data, tirzepatide is consistently producing larger mean weight losses than semaglutide in comparable populations. The mechanistic explanation is plausible: tirzepatide acts on both the GLP-1 and the GIP receptor, while semaglutide acts on the GLP-1 receptor only. Prescribing information for both drugs, available through DailyMed^[3], specifies the approved indications, contraindications, and dose titration schedules. Those details, along with insurance access and individual patient history, shape which drug is appropriate in a given case. This article is for educational purposes. Discuss treatment options with a qualified healthcare provider.

For per-country access and regulatory status, the tirzepatide page and the semaglutide page cover the approved indications, branded presentations, and jurisdiction-by-jurisdiction regulatory standing as of the date shown.